Analysis of G1/S checkpoint regulators in metastatic melanoma

Genes Chromosomes and Cancer

Volumn 28, Issue 4, 2000, Pages 404-414

  Sauroja, Ilari ^b   Smeds, Johanna ^a   Vlaykova, Tatyana ^c   Kumar, Rajiv ^c   Talve, Lauri ^c   Hahka Kemppinen, Marjo ^c   Punnonen, Kari ^c   Jansèn, Christer T ^c   Hemminki, Kari ^c   Pyrhönen, Seppo ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TURKU   (Finland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOMUSTINE; MALE; MELANOMA; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; S PHASE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0033932154     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2264(200008)28:4<404::AID-GCC6>3.0.CO;2-P     Document Type: Article

References (38)

1. Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N. 1999. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 91:446-451.
2. Bales ES, Dietrich C, Bandyopadhyay D, Schwahn DJ, Xu W, Didenko V, Leiss P, Conrad N, Pereira-Smith O, Orcngo I, Medrano EE. 1999. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol 113:1039-1046.
3. Buzzell RA, Zitelli JA. 1996. Favorable prognostic factors in recurrent and metastatic melanoma. J Am Acad Dermatol 34:798-803.
4. Funk JO, Schiller PI, Barrett MT, Wong DJ, Kind P, Sander CA. 1998. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol 25:291-296.
5. Glendening JM, Flores JF, Walker GJ, Stone S, Albino AP, Fountain JW. 1995. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res 55:5531-5535.
6. Gonzalgo ML, Bender CM, You EH, Glendening JM, Flores JF, Walker GJ, Hayward NK, Jones PA, Fountain JW. 1997. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 57:5336-5347.
7. Grover R, Chana JS, Wilson GD, Richman PI, Sanders R. 1998. An analysis of p16 protein expression in sporadic malignant melanoma. Melanoma Res 8:267-272.
8. Hahka-Kemppinen M, Muhonen T, Virolainen M, Jekunen A, Asko-Seljavaara S, Pyrhönen S. 1995. Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy. Br J Dermatol 132:973-977.
9. Hartmann A, Blaszyk H, Cunningham JS, McGovern RM, Schroeder JS, Helander SD, Pittelkow MR. Sommer SS, Kovach JS. 1996. Overexpression and mutations of p53 in metastatic malignant melanomas. Int J Cancer 67:313-317.
10. Kumar R, Lundh Rozell B, Louhelainen J, Hemminki K. 1998a. Mutations in the CDKN2A (p16INK4a) gene in microdissected sporadic primary melanomas. Int J Cancer 75:193-198.
11. Kumar R, Sauroja I, Punnonen K, Jansen C, Hemminki K. 1998b. Selective deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines. Genes Chromosomes Cancer 23:273-277.
12. Kumar R, Smeds J, Lundh Rozell B, Hemminki K. 1999. Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. Melanoma Res 9:138-147.
13. Lee JY, Dong SM, Shin MS, Kim SY, Lee SH, Kang SJ, Lee JD, Kirn CS, Kim SH, Yoo NJ. 1997. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. Biochem Biophys Res Com 237:667-672.
14. Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N, Hogg D. 1999. Mutation of the CDKN2A 5′LITR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21:128-132.
15. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, Kamb A. 1995. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10:1061-1067.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. 1981. Reporting results of cancer treatment. Cancer 47:207-214.
17. Morgan MB, Cowper SE. 1999. Expression of p27 (kip-1) in nevi and melanomas. Am J Dermatopathol 21:121-124.
18. Peris K, Chimenti S, Concetta F, Valeri P, Kerl H, Wolf P. 1999. UV fingerprint CDKN2a but no p14ARF mutations in sporadic melanomas. J Invest Dermatol 112:825-826.
19. Platz A, Hansson J, Ringborg U. 1998. Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study. Int J Cancer 78:13-15.
20. Pollock PM, Yu F, Qiu L, Parsons PG, Hayward NK. 1995. Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene 11:663-668.
21. Poremba C, Yandell DW, Metze D, Kamanabrou D, Bocker W, Dockhorn-Dworniczak B. 1995. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. Oncol Res 7:331-339.
22. Pyrhönen S, Hahka-Kemppinen M, Muhonen T. 1992. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 10:1919-1926.
23. Ruas M, Peters G. 1998. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378:F115-F177.
24. Saenz-Santamaria MC, McNutt NS, Bogdany JK, Shea CR. 1995a. p53 expression is rare in cutaneous melanomas. Am J Dermatopathol 17:344-349.
25. Saenz-Santamaria MC, McNutt NS, Shea CR. 1995b. Immunohistochemical expression of retinoblastoma protein in cutaneous melanomas. Br J Dermatol 133:890-895.
26. Sherr CJ. 1996. Cancer cell cycles. Science 274:1672-1677.
27. Sherr CJ. 1998. Tumor surveillance via the ARF-p53 pathway. Genes Dev 12:2984-2991.
28. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B. 1998. Prevalence of p16 and CDK4 germline mutations in 48 melanomaprone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7:209-216.
29. Sparrow LE, Eldon MJ, English DR, Heenan PJ. 1998. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 20:255-261.
30. Sparrow LE, Soong R, Dawkins HJ, Iacopetta BJ, Heenan PJ. 1995. p53 gene mutation and expression in naevi and melanomas. Melanoma Res 5:93-100.
31. Talve L, Kainu J, Collan Y, Ekfors T. 1996. Imnumohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin. Pathol Res Pract 192:825-833.
32. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T. 1997. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 74:255-259.
33. Trotter MJ, Tang L, Tron VA. 1997. Overexpression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in human cutaneous malignant melanoma. J Cutan Pathol 24:265-271.
34. Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW. 1998. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22:157-163.
35. Whiteman DC, Parsons PG, Green AC. 1998. p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 77:843-848.
36. Zerp SF, van Elsas A, Peltenburg LT, Schrier PI. 1999. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in mclanomagenesis. Br J Cancer 79:921-926.
37. Zhang Y, Xiong Y, Yarbrough WG. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.
38. Zhang Y, Xiong Y. 1999. Mutation in human ARF exon 2 disrupts its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 3:579-591.